Seattle Genetics (NASDAQ:SGEN) and Mateon Therapeutics (OTCMKTS:MATN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.
Risk & Volatility
Seattle Genetics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500.
This table compares Seattle Genetics and Mateon Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seattle Genetics||$654.70 million||18.54||-$222.69 million||($1.65)||-45.50|
|Mateon Therapeutics||N/A||N/A||-$2.74 million||N/A||N/A|
Mateon Therapeutics has lower revenue, but higher earnings than Seattle Genetics.
Institutional and Insider Ownership
99.8% of Seattle Genetics shares are held by institutional investors. 33.8% of Seattle Genetics shares are held by insiders. Comparatively, 10.6% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings and target prices for Seattle Genetics and Mateon Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Seattle Genetics currently has a consensus price target of $85.18, indicating a potential upside of 13.47%. Given Seattle Genetics’ stronger consensus rating and higher possible upside, analysts clearly believe Seattle Genetics is more favorable than Mateon Therapeutics.
This table compares Seattle Genetics and Mateon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Seattle Genetics beats Mateon Therapeutics on 7 of the 11 factors compared between the two stocks.
About Seattle Genetics
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
About Mateon Therapeutics
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.